Resistance to Targeted Therapies in Hematological Malignancies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 4577
Special Issue Editors
Interests: laboratory hematology; flow cytometry; cell immunophenotyping of hematological malignancies for immunology studies; development and validation of laboratory assays; external quality control
Interests: clinical hematology; acute leukemias; acute myeloid leukemia; immunophenotyping of hematological malignancies; allogeneic transplantation; measurable residual disease by flow cytometry and molecular techniques
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematological malignancies are successfully treated with chemo-immunotherapy in a large proportion of cases, with a limited rate of primary resistance. However, secondary resistance acquired during treatment appears to be an almost unavoidable occurrence, leading to relapse in approximately one third of patients. Targeted therapies, including monoclonal antibodies, conjugated or modified antibodies and small molecules, have replaced conventional chemotherapy in many clinical settings, since the latter approach has reached its limit of tolerability, which cannot be further improved.
Similar to microorganisms, malignant blood cells have an immense potential to avoid treatment, especially when targeted therapies are used as single agents. The resistance phenomena also affect CAR-modified effectors. The biological processes responsible for the resistance to targeted therapies are manifold, acting on the cell membrane with antigen loss or down-regulation, on the tumor microenvironment and effector–ligand relationship, or at genetic and epigenetic levels due to clonal evolution, mutations acquired during treatment or emerging subclones. Strategies aimed at counteracting the resistance to treatment are under intensive study.
The remission or relapse in hematological malignancies can be efficiently monitored by state-of-the art detection techniques using high-resolution multicolor flow cytometry and molecular assays, which can be tailored according to the disease involved and the specific targeted therapy.
Dr. Bruno Brando
Dr. Francesco Buccisano
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
